Dr. Hansen is co-founder and vice president of biology at Carmot Therapeutics, San Francisco, California. Carmot’s core technology is a revolutionary approach to identify new and improved drug-candidates by rapidly recombining and screening drug-fragments. Dr. Hansen’s research focuses on applying Carmot’s technology to develop innovative therapeutics for treating inflammatory and neurological diseases. Prior to starting Carmot, he was associate director of biology at Sunesis Pharmaceuticals, where he led programs in metabolic disease, auto-immunity, and oncology. Dr. Hansen was a Novartis Fellow of the Life Sciences Research Foundation in the laboratory of Dr. Tito Serafini, UC Berkeley, where he studied mammalian brain development. Dr. Hansen conducted his PhD studies in the laboratory of Dr. Robert Tjian at UC Berkeley, where he made several seminal discoveries in the field of transcriptional regulation. Dr. Hansen also holds an MS in biochemistry from the University of Copenhagen, Denmark.